| scholarly article | Q13442814 |
| P2093 | author name string | M. L. Stephenson | |
| P. C. Zamecnik | |||
| P2860 | cites work | Nucleotide sequence at the 5' terminus of the avian sarcoma virus genome | Q24561755 |
| Terminally repeated sequences in the avian sarcoma virus RNA genome | Q30449099 | ||
| Analysis of oncornavirus RNA subunits by electron microscopy | Q33266509 | ||
| Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide | Q33955866 | ||
| RNA-dependent DNA polymerase in virions of RNA tumour viruses | Q34206460 | ||
| Rous sarcoma virus genome is terminally redundant: the 5' sequence | Q35010030 | ||
| Rous sarcoma virus genome is terminally redundant: the 3' sequence | Q35010101 | ||
| Terminal redundancy and the origin of replication of Rous sarcoma virus RNA | Q35026426 | ||
| Rapid transformation of cells by Rous sarcoma virus | Q36449148 | ||
| Plaque assay of avian sarcoma viruses using casein | Q36539982 | ||
| Effects of polyadenylic acids on functions of murine RNA tumor viruses | Q36596094 | ||
| Use of arylsulfonyltriazoles for the synthesis of oligonucleotides by the triester approach | Q39963089 | ||
| Characterization of dna complementary to nucleotide sequences adjacent to poly(A) at the 3′-terminus of the avian sarcoma virus genome | Q40076224 | ||
| Characterization of dna complementary to nucleotide sequences at the 5′-terminus of the avian sarcoma virus genome | Q40076230 | ||
| Avian myeloblastosis virus RNA is terminally redundant: Implications for the mechanism of retrovirus replication | Q40097987 | ||
| Effects of a trinucleotide ethyl phosphotriester, Gmp(Et)Gmp(Et)U, on mammalian cells in culture | Q44405006 | ||
| The effects of reciprocal changes in temperature on the transformed state of cells infected with a rous sarcoma virus mutant | Q45821194 | ||
| Studies on polynucleotides. CII. The use of aromatic isocyanates for selective blocking of the terminal 3'-hydroxyl group in protected deoxyribooligonucleotides | Q70391219 | ||
| RNA dependent DNA polymerase activity in mammalian cells | Q93816808 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Rous sarcoma virus | Q1444330 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 280-284 | |
| P577 | publication date | 1978-01-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide | |
| P478 | volume | 75 |
| Q39516081 | -CH2- lengthening of the internucleotide linkage in the ApA dimer can improve its conformational compatibility with its natural polynucleotide counterpart |
| Q39584372 | 2'-Deoxy-2'-fluoro-beta-D-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies |
| Q40057883 | 2'-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA. |
| Q40958136 | 2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. |
| Q37201408 | 3'-modified antisense oligodeoxyribonucleotides complementary to calmodulin mRNA alter behavioral responses in Paramecium |
| Q38290099 | 5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy |
| Q36254686 | 99mTc-labeled nucleotides as tumor-seeking radiodiagnostic agents |
| Q34058587 | A BDNF autocrine loop in adult sensory neurons prevents cell death. |
| Q55075922 | A Dominant Negative Antisense Approach Targeting β-Catenin. |
| Q64927668 | A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. |
| Q73260509 | A High-Efficacy Antisense RIαPoly-DNP 21-nt RNA |
| Q38261831 | A Kinetic Model Explains Why Shorter and Less Affine Enzyme-recruiting Oligonucleotides Can Be More Potent |
| Q35212807 | A Potential of microRNAs for High-Content Screening |
| Q37144630 | A brief history, status, and perspective of modified oligonucleotides for chemotherapeutic applications |
| Q40504227 | A convenient approach to the synthesis of medium size oligodeoxyribonucleotides by improved new phosphite method |
| Q36441952 | A cytosine analog that confers enhanced potency to antisense oligonucleotides |
| Q28315030 | A general purpose RNA-cleaving DNA enzyme |
| Q36013890 | A genetic engineering strategy to eliminate peanut allergy |
| Q40566935 | A new 'sense' RNA approach to block viral RNA replication in vitro |
| Q39873975 | A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection |
| Q40393378 | A new approach to the synthesis of the 5'-deoxy-5'-methylphosphonate linked thymidine oligonucleotide analogues |
| Q38324450 | A peptide nucleic acid-aminosugar conjugate targeting transactivation response element of HIV-1 RNA genome shows a high bioavailability in human cells and strongly inhibits tat-mediated transactivation of HIV-1 transcription |
| Q40565140 | A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts |
| Q34522196 | A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. |
| Q38309661 | A selection strategy in plant transformation based on antisense oligodeoxynucleotide inhibition |
| Q40396975 | Activation and inactivation of gene expression using RNA sequences |
| Q37986972 | Advanced morpholino oligomers: a novel approach to antiviral therapy |
| Q60638540 | Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections |
| Q41526814 | Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides |
| Q37321859 | Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. |
| Q47325247 | Advances in therapeutic bacterial antisense biotechnology |
| Q44879918 | Alternative splicing in disease and therapy |
| Q64269362 | Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease |
| Q58875455 | Amino poly(glycerol methacrylate)s for oligonucleic acid delivery with enhanced transfection efficiency and low cytotoxicity |
| Q33854728 | An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines |
| Q36784168 | An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation |
| Q68556849 | Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography |
| Q35341682 | Anti-AIDS drug development: challenges and strategies |
| Q43706726 | Anti-HIV-1 activity of an antisense phosphorothioate oligonucleotide bearing imidazole and primary amine groups |
| Q28367621 | Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligodeoxynucleotides: penetration and localization of oligodeoxynucleotides in HIV-1-infected MOLT-4 cells |
| Q52640764 | Anti-miRNA oligonucleotides: A comprehensive guide for design. |
| Q38850010 | Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia |
| Q40505725 | Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16 |
| Q37200628 | Antimalarial activities of oligodeoxynucleotide phosphorothioates in chloroquine-resistant Plasmodium falciparum |
| Q38209252 | Antisense "pseudogenetics". |
| Q96302336 | Antisense Antibacterial Compounds |
| Q37063969 | Antisense Antivirals |
| Q33933892 | Antisense DNAs as multisite genomic modulators identified by DNA microarray |
| Q35118269 | Antisense DNAs as targeted genetic medicine to treat cancer |
| Q41526944 | Antisense Inhibition of Virus Infections |
| Q34911031 | Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy |
| Q38596893 | Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies. |
| Q38362937 | Antisense Oligonucleotides: Considerations for Lymphoma Therapy |
| Q53687216 | Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. |
| Q36584956 | Antisense RN |
| Q28373536 | Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycols |
| Q35790875 | Antisense approaches in prostate cancer |
| Q38327157 | Antisense c-myc oligodeoxyribonucleotide cellular uptake |
| Q34107762 | Antisense cancer therapy: the state of the science |
| Q47896067 | Antisense downregulation of SARS-CoV gene expression in Vero E6 cells |
| Q37859009 | Antisense drug discovery and development |
| Q41913548 | Antisense inhibition at the beta-secretase-site of beta-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576. |
| Q37080196 | Antisense oligodeoxynucleotide inhibition as a potent diagnostic tool for gene function in plant biology |
| Q28369354 | Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells |
| Q36334885 | Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects |
| Q40968139 | Antisense oligodeoxynucleotides as clinical therapeutic agents |
| Q38958094 | Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? |
| Q30398373 | Antisense oligonucleotide inhibits avian influenza virus H5N1 replication by single chain antibody delivery system |
| Q35049576 | Antisense oligonucleotide therapy for urologic tumors |
| Q34284377 | Antisense oligonucleotide treatments for psoriasis |
| Q33916097 | Antisense oligonucleotides as a tool for gene functionalization and target validation |
| Q50587585 | Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. |
| Q35179429 | Antisense oligonucleotides for cancer therapy-an overview |
| Q34305862 | Antisense oligonucleotides in cutaneous therapy |
| Q55018458 | Antisense oligonucleotides in neurological disorders. |
| Q36040819 | Antisense oligonucleotides in the treatment of bladder cancer |
| Q38293518 | Antisense oligonucleotides, microRNAs, and antibodies. |
| Q33970374 | Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease |
| Q35568911 | Antisense technology in molecular and cellular bioengineering. |
| Q77297328 | Antisense therapeutics |
| Q33864554 | Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems |
| Q35153742 | Antisense therapeutics: from theory to clinical practice |
| Q33826614 | Antisense therapeutics: is it as simple as complementary base recognition? |
| Q36133133 | Antisense therapy for cancer |
| Q34992794 | Antisense therapy for cancer--the time of truth |
| Q41649099 | Antisense therapy for lymphomas |
| Q34341868 | Antisense therapy in oncology: new hope for an old idea? |
| Q45754951 | Antisense therapy of hepatitis B virus infection |
| Q73727512 | Antisense therapy of influenza |
| Q28345950 | Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma |
| Q37189998 | Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? |
| Q36458427 | Antisense-based cancer therapeutics: are we there yet? |
| Q38340328 | Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. |
| Q24682555 | Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications |
| Q41522945 | Antisense—Protein Kinase A: A Single-Gene-Based Therapeutic Approach |
| Q35956779 | Antiviral activity and possible mechanisms of action of oligonucleotides-poly(L-lysine) conjugates targeted to vesicular stomatitis virus mRNA and genomic RNA. |
| Q40433521 | Antiviral agents in dermatology: current status and future prospects |
| Q35601772 | Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q35597089 | Approaches for the sequence-specific knockdown of mRNA. |
| Q28833658 | Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells |
| Q34542523 | Approaches to antiviral drug development |
| Q36939779 | Argonaute 2-dependent Regulation of Gene Expression by Single-stranded miRNA Mimics |
| Q87422386 | Assessing unintended hybridization-induced biological effects of oligonucleotides |
| Q34540878 | Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents |
| Q35066323 | Association of 2'-5' oligoribonucleotides |
| Q40428323 | Backbone modifications in oligonucleotides and peptide nucleic acid systems |
| Q34343478 | BioShuttle mobility in living cells studied with high-resolution FCS & CLSM methodologies |
| Q24801934 | Biochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseases |
| Q71033910 | Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumour xenograft following intratumoral injection |
| Q45753100 | Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection |
| Q35237618 | Biologic and therapeutic significance of MYB expression in human melanoma |
| Q39003630 | Biological applications of xeno nucleic acids. |
| Q40398950 | Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3'hydroxypropylamine oligonucleotide |
| Q38298394 | Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors |
| Q37259329 | Breeding for disease resistance--the prospective role of genetic manipulation |
| Q40224978 | Can hammerhead ribozymes be efficient tools to inactivate gene function? |
| Q47854521 | Capillary gel electrophoresis of therapeutic oligonucleotides--analysis of single- and double-stranded forms |
| Q82476875 | Cationic nucleolipids as efficient siRNA carriers |
| Q40876347 | Cell delivery and mechanisms of action of antisense oligonucleotides |
| Q37013966 | Cell penetrating peptide conjugates of steric block oligonucleotides |
| Q57291698 | Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment |
| Q38974187 | Cell-Penetrating Peptides for Antiviral Drug Development |
| Q36272601 | Cell-specific targeting of lipid-based carriers for ODN and DNA. |
| Q45882462 | Cellular effects of antisense c-myc oligodeoxynucleotides are delivery dependent |
| Q36532644 | Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides |
| Q40596728 | Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line |
| Q37944929 | Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. |
| Q38424377 | Cellular uptake and intracellular trafficking of oligonucleotides |
| Q37907407 | Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. |
| Q59132439 | Changes in lipid metabolism convey acid tolerance in |
| Q91901464 | Chapter 3 Antiviral drugs: general considerations |
| Q38300743 | Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin |
| Q92731133 | Chemical Diversity of Locked Nucleic Acid-Modified Antisense Oligonucleotides Allows Optimization of Pharmaceutical Properties |
| Q34200255 | Chemical modification and design of anti-miRNA oligonucleotides. |
| Q36101387 | Chemical modification of gene silencing oligonucleotides for drug discovery and development |
| Q48569299 | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs |
| Q40379692 | Cholesterol conjugated oligonucleotide and LNA: a comparison of cellular and nuclear uptake by Hep2 cells enhanced by streptolysin-O. |
| Q28359555 | Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture |
| Q38297610 | Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors |
| Q40389198 | Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages |
| Q40546194 | Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro |
| Q89411864 | Complex consisting of antisense DNA and β-glucan promotes internalization into cell through Dectin-1 and hybridizes with target mRNA in cytosol |
| Q52249360 | Conformational studies of antisense DNA by PFG NMR. |
| Q58001525 | Conjugation of DNA with Biomolecules and Nanoparticles |
| Q38077761 | Context-specific microRNA function in developmental complexity. |
| Q41141202 | Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition |
| Q37529859 | Controlled delivery of antisense oligonucleotides: a brief review of current strategies. |
| Q34050432 | Coupling strategies for the synthesis of Peptide-oligonucleotide conjugates for patterned synthetic biomineralization |
| Q24608092 | Crystallographic studies of chemically modified nucleic acids: a backward glance |
| Q64056999 | Current Progress on MicroRNA-Based Gene Delivery in the Treatment of Osteoporosis and Osteoporotic Fracture |
| Q34311089 | Current status of ribozymes as gene therapy agents for cancer |
| Q34522704 | DNA analogues: from supramolecular principles to biological properties |
| Q35858691 | DNA and RNA derivatives to optimize distribution and delivery |
| Q41581768 | DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors |
| Q38378692 | DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes. |
| Q27024646 | Delivery of oligonucleotides with lipid nanoparticles |
| Q39021948 | Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides (deoxyribozymes): from cell culture studies to clinical trials |
| Q38369597 | Delivery of therapeutic oligonucleotides with cell penetrating peptides. |
| Q36631534 | Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo |
| Q37970644 | Deoxyribozymes and bioinformatics: complementary tools to investigate axon regeneration |
| Q35228538 | Deoxyribozymes: new therapeutics to treat central nervous system disorders |
| Q40872656 | Depletion of casein kinase II by antisense oligonucleotide prevents neuritogenesis in neuroblastoma cells. |
| Q36783179 | Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice |
| Q34300807 | Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents |
| Q30884698 | Design and applications of modified oligonucleotides |
| Q38089175 | Design and development of antisense drugs. |
| Q44622097 | Determination of the Absolute P-Configuration of a Phthalidyl-Phosphonate Thymidine-Thymidine Dimer |
| Q24632876 | Determinator-inhibitor pairs as a mechanism for threshold setting in development: a possible function for pseudogenes |
| Q89352359 | Developing antisense oligonucleotide and short-interfering RNA therapeutics - a few considerations |
| Q36174842 | Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering |
| Q41121288 | Development of antisense and antigene oligonucleotide analogs. |
| Q73387828 | Differential effects of intrastriatally infused fully and endcap phosphorothioate antisense oligonucleotides on morphology, histochemistry and prodynorphin expression in rat brain |
| Q81131655 | Disulfide conjugation of peptides to oligonucleotides and their analogs |
| Q34331745 | Does chemistry have a future in therapeutic innovations? |
| Q42754723 | Dorsal skinfold chamber technique for intravital microscopy in nude mice |
| Q36069684 | Dosimetry and risk from low- versus high-LET radiation of Auger events and the role of nuclide carriers |
| Q52062399 | Downregulation of gene expression with negatively charged peptide nucleic acids (PNAs) in zebrafish embryos. |
| Q57744033 | Drastic Stabilization of Parallel DNA Hybridizations by a Polylysine Comb-Type Copolymer with Hydrophilic Graft Chain |
| Q34363078 | Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. |
| Q38264255 | Effect of Terminal Groups of Dendrimers in the Complexation with Antisense Oligonucleotides and Cell Uptake. |
| Q44347403 | Effect of supraspinal antisense oligodeoxynucleotide treatment on delta-opioid receptor mRNA levels in mice |
| Q35749594 | Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli |
| Q39185508 | Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549. |
| Q41119207 | Effects of oligodeoxynucleotides on the physicochemical characteristics and cellular uptake of liposomes |
| Q33872170 | Efficient silencing of gene expression by an ASON-bulge-DNAzyme complex |
| Q35158452 | Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. |
| Q41192925 | Electronic Structures of LNA Phosphorothioate Oligonucleotides |
| Q35154985 | Electroporation and microinjection successfully deliver single-stranded and duplex DNA into live cells as detected by FRET measurements. |
| Q37588723 | Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease |
| Q38305614 | Endless: a purine-binding RNA motif that can be expressed in cells. |
| Q44148116 | Engineered RNase P ribozymes increase their cleavage activities and efficacies in inhibiting viral gene expression in cells by enhancing the rate of cleavage and binding of the target mRNA. |
| Q35212574 | Engineering of RNase P ribozyme for gene-targeting applications |
| Q37655781 | Enhanced splice correction by 3', 5'-serinol and 2'-(ω-O-methylserinol) guarded OMe-RNA/DNA mixmers in cells |
| Q34686105 | Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents |
| Q44998465 | Enzymatic and hybridization properties of oligonucleotide analogs containing novel phosphoramidate internucleotide linkages |
| Q34976847 | Enzymatic synthesis of modified oligonucleotides by PEAR using Phusion and KOD DNA polymerases |
| Q36169056 | Epigenetic manipulation of gene expression: a toolkit for cell biologists |
| Q37967638 | Etiology of potentially primordial biomolecular structures: from vitamin B12 to the nucleic acids and an inquiry into the chemistry of life's origin: a retrospective |
| Q54073336 | Evaluation of different types of end-capping modifications on the stability of oligonucleotides toward 3'- and 5'-exonucleases. |
| Q40240405 | Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA. |
| Q40650358 | Expression of an RNase P ribozyme against the mRNA encoding human cytomegalovirus protease inhibits viral capsid protein processing and growth |
| Q45846920 | Expression of antisense RNA fails to inhibit influenza virus replication |
| Q36774832 | Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication |
| Q38316976 | Facilitating RNA structure prediction with microarrays |
| Q30972411 | Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to antisense oligonucleotides by application of secondary structure predictions and RNase H in combination with MALDI-TOF mass spectrometry |
| Q25256817 | Fast-track applications: the potential for direct delivery of proteins and nucleic acids to plant cells for the discovery of gene function |
| Q38669913 | Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides |
| Q33804044 | Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis |
| Q38334375 | Function of the Homeodomain Protein GHF1 in Pituitary Cell Proliferation |
| Q35565479 | Functional genomics and radioisotope-based imaging procedures |
| Q36642722 | Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications |
| Q39202309 | Functionalization of the 3'-ends of DNA and RNA strands with N-ethyl-N-coupled nucleosides: a promising approach to avoid 3'-exonuclease-catalyzed hydrolysis of therapeutic oligonucleotides. |
| Q46566925 | Gas-phase dissociation of oligoribonucleotides and their analogs studied by electrospray ionization tandem mass spectrometry |
| Q30449973 | Gene expression from both intronless and intron-containing Rous sarcoma virus clones is specifically inhibited by anti-sense RNA |
| Q38802501 | Gene regulation and genetics in neurochemistry, past to future. |
| Q33637644 | Gene therapy and vascular disease |
| Q34108056 | Gene therapy for brain tumors |
| Q25256700 | Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. |
| Q41395911 | Gene-targeted inhibition of transactivation of human immunodeficiency virus type-1 (HIV-1)-LTR by antisense oligonucleotides |
| Q38000999 | Genetic engineering of plants for virus resistance |
| Q37010620 | Genetic modification of stem cells for transplantation |
| Q38340724 | Growth factors in gliomas: antisense and dominant negative mutant strategies |
| Q71791191 | Helix-Stabilizing Agent, CC-1065, Enhances Suppression of Translation by an Antisense Oligodeoxynucleotide |
| Q55652601 | High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition |
| Q33285354 | High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides |
| Q73323687 | Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex |
| Q40916373 | Homologous human and murine antisense oligonucleotides targeting stat6. Functional effects on germline cepsilon transcript |
| Q56863833 | How the gene behind Huntington’s disease could be neutralized |
| Q40778337 | Human cell lines expressing hormone regulated T7 RNA polymerase localized at distinct intranuclear sites |
| Q33552402 | Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. |
| Q35080708 | Hybrid characteristics of oligonucleotides consisting of isonucleoside 2',5'-anhydro-3'-deoxy-3'-(thymin-1-yl)-D-mannitol with different linkage modes |
| Q38300582 | Hybridization of 2'-ribose modified mixed-sequence oligonucleotides: thermodynamic and kinetic studies |
| Q36937561 | ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense? |
| Q40532462 | Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. |
| Q33614680 | Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells |
| Q55260229 | Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice. |
| Q33916110 | Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides |
| Q92596908 | In Vitro Validation of Phosphorodiamidate Morpholino Oligomers |
| Q35229611 | In situ detection of a heat-shock regulatory element binding protein using a soluble synthetic enhancer sequence |
| Q42953784 | In vitro analysis of ribozyme-mediated knockdown of an ADRP associated rhodopsin mutation |
| Q35935052 | In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription |
| Q38322149 | In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts |
| Q34859948 | In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation |
| Q48488864 | In vivo imaging of oligonucleotides with positron emission tomography |
| Q34047054 | In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. |
| Q98243955 | In vivo knockdown of SK3 channels using antisense oligonucleotides protects against atrial fibrillation in rats |
| Q38312873 | Incorporation of a 4-hydroxy-N-acetylprolinol nucleotide analogue improves the 3'-exonuclease stability of 2'-5'-oligoadenylate-antisense conjugates |
| Q39747859 | Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2X3 receptor |
| Q37139757 | Informational Drugs: A New Concept in Pharmacology |
| Q47682874 | Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide |
| Q33955866 | Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide |
| Q28361132 | Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates |
| Q41415372 | Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen |
| Q40520429 | Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives |
| Q28316278 | Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine |
| Q36873260 | Inhibition of human immunodeficiency virus by using an oligonucleoside methylphosphonate targeted to the tat-3 gene. |
| Q28355337 | Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their phosphorothioate analogues |
| Q33635256 | Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides |
| Q40062719 | Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. |
| Q33563974 | Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides |
| Q37133075 | Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides |
| Q35610321 | Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. |
| Q36902897 | Inhibition of retroviral replication by anti-sense RNA |
| Q35840982 | Inhibition of simian virus 40 DNA replication in CV-1 cells by an oligodeoxynucleotide covalently linked to an intercalating agent |
| Q41523563 | Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action |
| Q70196224 | Inhibition of thymidine kinase gene expression by anti-sense RNA: A molecular approach to genetic analysis |
| Q36687440 | Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. |
| Q35186336 | Innovations in oligonucleotide drug delivery |
| Q37783034 | Innovations in the use of antisense oligonucleotides |
| Q40398651 | Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET). |
| Q33959229 | Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model |
| Q36040788 | Intratumoural administration of dendritic cells: hostile environment and help by gene therapy |
| Q50447519 | Invention and Early History of Morpholinos: From Pipe Dream to Practical Products. |
| Q26852160 | Involvement of long noncoding RNAs in diseases affecting the central nervous system |
| Q42322021 | Iron Oxide Nanoparticles Coated with a Phosphorothioate Oligonucleotide and a Cationic Peptide: Exploring Four Different Ways of Surface Functionalization |
| Q52858958 | Isolation of Pyrimidine Isostichs from Chick Erythrocyte DNA |
| Q36880000 | Kinetics of phosphorothioate oligonucleotide metabolism in biological fluids |
| Q37556115 | Knockdown of Inhibitory Guanine Nucleotide Binding Protein Giα-2 by Antisense Oligodeoxynucleotides Attenuates the Development of Hypertension and Tachycardia in Spontaneously Hypertensive Rats |
| Q28082939 | Knocking down disease: a progress report on siRNA therapeutics |
| Q91909108 | Leveraging Antisense Technology in the Lungs: RNA-Targeting Therapies for Respiratory Diseases |
| Q35227295 | Lexitropsins in antiviral drug development |
| Q43759394 | Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. |
| Q31967436 | Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. |
| Q45778654 | M13 bacteriophage DNA inhibits duck hepatitis B virus during acute infection |
| Q47438944 | Making sense of antisense oligonucleotides: A narrative review |
| Q38332235 | Malaria merozoite surface protein antisense oligodeoxynucleotides lack antisense activity but function as polyanions to inhibit red cell invasion |
| Q39873462 | Marek's disease virus (MDV) ICP4, pp38, and meq genes are involved in the maintenance of transformation of MDCC-MSB1 MDV-transformed lymphoblastoid cells |
| Q34299285 | Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? |
| Q36798960 | Mechanisms of the inhibition of reverse transcription by antisense oligonucleotides |
| Q38316118 | Mechanisms of the inhibition of reverse transcription by unmodified and modified antisense oligonucleotides |
| Q45147307 | Medicine: a cholesterol connection in RNAi |
| Q61450447 | Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties |
| Q38346212 | Metal-bipyridine complexes in DNA backbones and effects on thermal stability |
| Q37726449 | MicroRNA-mediated gene silencing |
| Q37032639 | MicroRNAs as targets for antisense-based therapeutics |
| Q36316652 | Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. |
| Q40412118 | Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions |
| Q33228950 | Modulation of tracer accumulation in malignant tumors: gene expression, gene transfer, and phage display |
| Q38770075 | Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. |
| Q42293314 | Molecular Mechanisms of Antisense Oligonucleotides |
| Q40599028 | Molecular therapeutic strategies in hepatitis B virus infection |
| Q27642301 | NMR structure of an -L-LNA:RNA hybrid: structural implications for RNase H recognition |
| Q39782719 | Native oligodeoxynucleotides specifically active against human immunodeficiency virus type 1 in vitro: a G-quartet-driven effect? |
| Q41561845 | Natural antisense RNA/target RNA interactions: possible models for antisense oligonucleotide drug design |
| Q42589910 | Nearest neighbor parameters for Watson-Crick complementary heteroduplexes formed between 2'-O-methyl RNA and RNA oligonucleotides |
| Q37220809 | New Drugs: Antisense Agents in Cancer Research and Therapeutics |
| Q42153007 | New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. |
| Q38904908 | Non-coding RNAs as drug targets |
| Q39094440 | Noncoding RNA for Cancer Gene Therapy |
| Q38337527 | Non–Sequence-Specific Inhibition of Transferrin Receptor Expression in HL-60 Leukemia Cells by Phosphorothioate Oligodeoxynucleotides |
| Q36925191 | Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents |
| Q42125955 | Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum |
| Q90743959 | Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides |
| Q33576701 | Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint |
| Q47134784 | Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides |
| Q41667366 | Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection |
| Q38591847 | Nucleic acid-based drugs against emerging zoonotic viruses |
| Q37338992 | Nucleic acids-based therapeutics in the battle against pathogenic viruses |
| Q48475893 | Obituary: Paul C. Zamecnik (1912-2009). |
| Q33650315 | Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus |
| Q36061093 | Oligodeoxynucleotides as antisense inhibitors of gene expression |
| Q37833455 | Oligomeric nucleic acids as antivirals. |
| Q27002403 | Oligonucleotide Therapies: The Past and the Present |
| Q47248989 | Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNase H. |
| Q38618638 | Oligonucleotide therapeutics: chemistry, delivery and clinical progress |
| Q48288187 | Oligonucleotide therapies for disorders of the nervous system |
| Q92343873 | Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases |
| Q34300042 | Oligonucleotide treatment of ras-induced tumors in nude mice |
| Q30353665 | Oligonucleotide-based antiviral strategies. |
| Q36124734 | Oligonucleotides and polyribonucleotides: a review of antiviral activity |
| Q37053596 | Oligonucleotides as therapeutic agents |
| Q54539826 | Oligonucleotides comprised of alternating 2'-deoxy-2'-fluoro-beta-D-arabinonucleosides and D-2'-deoxyribonucleosides (2'F-ANA/DNA 'altimers') induce efficient RNA cleavage mediated by RNase H. |
| Q34609056 | Oligonucleotides with rapid turnover of the phosphate groups occur endogenously in eukaryotic cells |
| Q37937557 | Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases |
| Q38986192 | One-bead coarse-grained model for RNA dynamics. |
| Q37867701 | Opportunities and challenges for the development of antisense treatment in neuromuscular disorders |
| Q35210840 | Oral Virus Infections: The Potential for Gene Transfer in Treatment and Prevention |
| Q30235525 | Overcoming cellular barriers for RNA therapeutics |
| Q41760845 | Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups |
| Q42226373 | Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. |
| Q37347451 | Peptide-mediated cellular delivery of oligonucleotide-based therapeutics in vitro: quantitative evaluation of overall efficacy employing easy to handle reporter systems |
| Q52677688 | Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma. |
| Q40504539 | Pharmacokinetics of antisense oligonucleotides |
| Q36534674 | Pharmacologic control of specific gene expression |
| Q33716194 | Pharmacology of antisense oligonucleotide inhibitors of protein expression |
| Q28361672 | Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus |
| Q37933197 | Phosphorothioate nucleotides and oligonucleotides - recent progress in synthesis and application |
| Q72420656 | Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses |
| Q40814102 | Photodynamic antisense regulation of human cervical carcinoma cell growth using psoralen-conjugated oligo(nucleoside phosphorothioate). |
| Q58200477 | Physicochemical characterization of protamine-phosphorothioate nanoparticles |
| Q42418345 | Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides |
| Q38110474 | Polyethylenimines for siRNA and miRNA delivery in vivo |
| Q34160291 | Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides |
| Q33770561 | Preclinical and clinical pharmacology of antisense oligonucleotides |
| Q40423074 | Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices |
| Q52453836 | Production of phenocopies by Krüppel antisense RNA injection into Drosophila embryos. |
| Q40785126 | Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effects |
| Q89805468 | Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement |
| Q89611723 | Progress toward the development of the small molecule equivalent of small interfering RNA |
| Q28297652 | Progress towards in vivo use of siRNAs |
| Q30230272 | Progress towards the treatment of Ebola haemorrhagic fever |
| Q38315776 | Pseudo-cyclic oligonucleotides: in vitro and in vivo properties |
| Q74549978 | Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes |
| Q35556491 | Quantitative hybridization-arrest of mRNA in Xenopus oocytes using single-stranded complementary DNA or oligonucleotide probes |
| Q38405255 | Quantum mechanical studies of DNA and LNA. |
| Q38014158 | Quantum rods as nanocarriers of gene therapy. |
| Q54295403 | Quick regulation of mRNA functions by a few seconds of photoirradiation. |
| Q99417440 | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges |
| Q47786398 | RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions |
| Q92162442 | RNA Therapeutics: How Far Have We Gone? |
| Q36508943 | RNA interference for antiviral therapy |
| Q34248493 | RNA therapeutics: beyond RNA interference and antisense oligonucleotides |
| Q40539121 | RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds |
| Q44166409 | RNase P ribozymes for the studies and treatment of human cytomegalovirus infections |
| Q50761096 | Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs |
| Q36228762 | Rational Design of Small Molecules Targeting Oncogenic Noncoding RNAs from Sequence |
| Q35130605 | Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation |
| Q33325053 | Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides |
| Q77657247 | Reading DNA differently |
| Q33601089 | Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking |
| Q40125088 | Recombinant DNA technology. |
| Q44525679 | Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy |
| Q90044813 | Reduction of integrin alpha 4 activity through splice modulating antisense oligonucleotides |
| Q40450702 | Regiospecific inhibition of DNA duplication by antisense phosphate-methylated oligodeoxynucleotides |
| Q40625609 | Regulation of endothelial cell adhesion molecule expression with antisense oligonucleotides |
| Q24547040 | Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers |
| Q28339853 | Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells |
| Q64268645 | Retro-1-Oligonucleotide Conjugates. Synthesis and Biological Evaluation |
| Q34332264 | Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. |
| Q40374816 | Ribozyme mimics as catalytic antisense reagents. |
| Q33631283 | Role of RNase H in hybrid-arrested translation by antisense oligonucleotides |
| Q35975656 | Role of Toll-like receptors in antisense and siRNA [corrected]. |
| Q52362632 | Selection and Characterization of a DNA Aptamer Specifically Targeting Human HECT Ubiquitin Ligase WWP1. |
| Q35323830 | Selective inhibition of Escherichia coli protein synthesis and growth by nonionic oligonucleotides complementary to the 3′ end of 16S rRNA |
| Q34727939 | Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent |
| Q48364788 | Self-neutralizing oligonucleotides with enhanced cellular uptake. |
| Q40517590 | Sequence dependent effects in methylphosphonate deoxyribonucleotide double and triple helical complexes |
| Q42803620 | Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide |
| Q29039090 | Silencing disease genes in the laboratory and the clinic |
| Q34302693 | Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4 |
| Q37696968 | Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides |
| Q34405044 | Small RNA- and DNA-based gene therapy for the treatment of liver cirrhosis, where we are? |
| Q37793079 | Smart siRNA Delivery Systems Based on Polymeric Nanoassemblies and Nanoparticles |
| Q29999315 | Solid-Phase Supports for Oligonucleotide Synthesis |
| Q40598448 | Solid-Phase Synthesis of Oligodeoxynucleotide Analogs Containing Phosphorodithioate Linkages |
| Q40495421 | Some substrate properties of analogues of oligothymidylates with p-s-C5′bonds |
| Q34321871 | Specific gene suppression by engineered ribozymes in monkey cells |
| Q40983867 | Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells |
| Q36355716 | Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones |
| Q35592008 | Specific inhibition of mRNA translation by complementary oligonucleotides covalently linked to intercalating agents |
| Q40104485 | Specific targets for antiviral drugs. |
| Q44652403 | Stabilisation of RNA Bulges by Oligonucleotide Complements Containing an Adenosine Analogue |
| Q38303734 | Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond |
| Q35241689 | Status of ribozyme and antisense-based developmental approaches for anti-HIV-1 therapy |
| Q28319929 | Structure-activity relationships and mode of action of 5-mercapto-substituted oligo- and polynucleotides as antitemplates inhibiting replication of human immunodeficiency virus type 1 |
| Q45287505 | Studies on antisense inhibition of translation in vitro. Anomalies and re-evaluation |
| Q77327291 | Study of phosphorothioate-modified oligonucleotide resistance to 3'-exonuclease using capillary electrophoresis |
| Q38304026 | Study of stimulus-secretion coupling in single cells using antisense oligodeoxynucleotides and patch-clamp techniques to inhibit specific protein expression |
| Q34366036 | Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system |
| Q42127144 | Substrate Specificity and Kinetics of Degradation of Antisense Oligonucleotides by a 3′ Exonuclease in Plasma |
| Q73572065 | Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides |
| Q35549395 | Synthesis and application of functional peptides as cell nucleus‐directed molecules in the treatment of malignant diseases |
| Q33992677 | Synthesis and biological evaluation of 2',4'- and 3',4'-bridged nucleoside analogues. |
| Q38320810 | Synthesis and biophysical studies of modified oligonucleotides containing acyclic amino alcohol nucleoside analogs |
| Q73485764 | Synthesis and characterization of a tetranucleotide analogue containing alternating phosphonate-amide backbone linkages |
| Q75313735 | Synthesis and hybridization properties of l-oligodeoxynucleotide analogues fixed in a low anti glycosyl conformation |
| Q38527452 | Synthesis and hybridization property of sugar and phosphate linkage modified oligonucleotides |
| Q43920974 | Synthesis and structural studies of S-type/N-type-locked/frozen nucleoside analogues and their incorporation in RNA-selective, nuclease resistant 2'-5' linked oligonucleotides |
| Q38343786 | Synthesis of alkylating oligonucleotide derivatives containing cholesterol or phenazinium residues at their 3'-terminus and their interaction with DNA within mammalian cells |
| Q58036274 | Synthesis of defined peptide-oligonucleotide hybrids containing a nuclear transport signal sequence |
| Q35751723 | Synthesis of human insulin gene. Part I. Development of reversed-phase chromatography in the modified triester method. Its application in the rapid and efficient synthesis of eight deoxyribo-oligonucleotides fragments constituting human insulin A DNA |
| Q37586371 | Synthesis of specific diastereomers of a DNA methylphosphonate heptamer, d(CpCpApApApCpA), and stability of base pairing with the normal DNA octamer d(TPGPTPTPTPGPGPC). |
| Q55409536 | Synthesis, Affinity for Complementary RNA and DNA, and Enzymatic Stability of Triazole-Linked Locked Nucleic Acids (t-LNAs). |
| Q40517947 | Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates |
| Q38331315 | Synthetic antisense oligodeoxynucleotides to transiently suppress different nucleus- and chloroplast-encoded proteins of higher plant chloroplasts |
| Q38136096 | Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases |
| Q64115674 | Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro |
| Q37271928 | Systemic cancer therapy: evolution over the last 60 years |
| Q44986711 | Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response |
| Q52584544 | Tapping the RNA world for therapeutics. |
| Q64039292 | Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases |
| Q37147772 | Targeted therapy of cancer: new roles for pathologists--prostate cancer |
| Q36050408 | Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer |
| Q42478897 | Targeting Host E-Selectin Expression by Antisense Oligodeoxynucleotides as Potential Antiendotoxin TherapyIn Vivo |
| Q36028877 | Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells |
| Q36100236 | Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera |
| Q38329856 | Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense |
| Q90288801 | Targeting mRNA processing as an anticancer strategy |
| Q34388246 | Targeting the Mycobacterium tuberculosis 30/32-kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle by using antisense technology. |
| Q73371194 | Ten years of antisense inhibition of brain G-protein-coupled receptor function |
| Q91715704 | The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer |
| Q52738891 | The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders. |
| Q72292673 | The anti-proliferative effect of proliferating cell nuclear antigen-specific antisense oligonucleotides on human gastric cancer cell lines |
| Q74142781 | The anticonvulsant properties of antisense c-fos oligodeoxynucleotides in kainic acid-induced seizures |
| Q39154511 | The chemical evolution of oligonucleotide therapies of clinical utility |
| Q40417648 | The common 5' terminal sequence on trypanosome mRNAs: a target for anti-messenger oligodeoxynucleotides. |
| Q96816785 | The delivery challenge: fulfilling the promise of therapeutic genome editing |
| Q34756466 | The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis |
| Q36435632 | The future of antisense oligonucleotides in the treatment of respiratory diseases |
| Q24812616 | The influence of locked nucleic acid residues on the thermodynamic properties of 2'-O-methyl RNA/RNA heteroduplexes |
| Q34026169 | The many twists and turns of DNA: template, telomere, tool, and target |
| Q34030102 | The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease |
| Q36881830 | The potential use of catalytic RNAs in therapy of HIV infection and other diseases |
| Q40639075 | The role of the 5' untranslated region of eukaryotic messenger RNAs in translation and its investigation using antisense technologies. |
| Q33788813 | The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals |
| Q30450778 | The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos |
| Q46477875 | The state of the art in antisense research |
| Q40772611 | The use of antisense approaches to study development |
| Q41914615 | The use of nano-sized acicular material, sliding friction, and antisense DNA oligonucleotides to silence bacterial genes |
| Q34473470 | The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. |
| Q36897394 | The versatility of oligonucleotides as potential therapeutics |
| Q26782089 | Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis |
| Q28818017 | Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides |
| Q34244756 | Therapeutic RNA manipulation in liver disease. |
| Q49961986 | Therapeutic Targeting of Long Non-Coding RNAs in Cancer |
| Q37038988 | Therapeutic applications of aptamers |
| Q35153579 | Therapeutic applications of oligonucleotides |
| Q37457903 | Therapeutic potential of RNA interference in pain medicine |
| Q35234713 | Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells |
| Q41337511 | Towards genomic drug therapy with antisense oligonucleotides |
| Q77376171 | Towards the structure-based design of oligonucleotide therapeutics |
| Q38300047 | Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer |
| Q35078374 | Transcriptional tools for aging research |
| Q57556362 | Translating chitosan to clinical delivery of nucleic acid-based drugs |
| Q47785506 | Translational inhibition of messenger RNA of the human pi class glutathione S-transferase by antisense oligodeoxyribonucleotides |
| Q73997997 | Translational suppression by hammerhead ribozymes and inactive variants in S. cerevisiae |
| Q40468453 | Treatment of AIDS with Drugs Targeted to Inhibit Different Stages of the HIV Life Cycle |
| Q30325785 | Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication. |
| Q84031085 | Trioligonucleotide reagents: addressed RNA modification |
| Q48035835 | Tuning the hybridization properties of modified oligonucleotides: from flexible to conformationally constrained phosphonate internucleotide linkages. |
| Q39511181 | Uptake, Intracellular Distribution, and Stability of Oligodeoxynucleotide Phosphorothioate bySchistosoma mansoni |
| Q36254793 | Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q37938423 | Using drug-excipient interactions for siRNA delivery |
| Q74552680 | Viral targets for antisense oligonucleotides: a mini review |
| Q82587596 | What history tells us XIV. Regulation of gene expression by non-coding RNAs: the early steps |
| Q81439383 | [Antisense therapy in oncology: present situation] |
| Q39722977 | alpha-Oligodeoxyribonucleotide N3'-->P5' phosphoramidates: synthesis and duplex formation |
| Q26741950 | mRNA-Based Therapeutics - Advances and Perspectives |
| Q36373107 | siRNA-based approaches in cancer therapy |
| Q45749998 | β-1,3-Glucan/antisense oligonucleotide complex stabilized with phosphorothioation and its gene suppression |
Search more.